Lunatic Fringe Deficiency Cooperates with the Met/Caveolin Gene Amplicon to Induce Basal-like Breast Cancer

Cancer Cell

Volumn 21, Issue 5, 2012, Pages 626-641

  Xu, Keli ^a,i   Usary, Jerry ^b   Kousis, Philaretos C ^a   Prat, Aleix ^b   Wang, Dong Yu ^c   Adams, Jessica R ^a,e   Wang, Wei ^a   Loch, Amanda J ^a   Deng, Tao ^d   Zhao, Wei ^b   Cardiff, Robert Darrell ^f   Yoon, Keejung ^g,j   Gaiano, Nicholas ^g   Ling, Vicki ^a   Beyene, Joseph ^a,k   Zacksenhaus, Eldad ^d   Gridley, Tom ^h   Leong, Wey L ^c   Guidos, Cynthia J ^a,e   Perou, Charles M ^b   Egan, Sean E ^a,c   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Maine Medical Center Research Institute   (United States)

ⁱ UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^j Sungkyunkwan University   (South Korea)

^k MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN; JAGGED1; LFNG PROTEIN; NOTCH RECEPTOR; SCATTER FACTOR RECEPTOR; TRANSFERASE; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL LIKE BREAST CANCER; BREAST TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE LOCUS; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL;

EID: 84861398396     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.03.041     Document Type: Article

References (83)

1. Andrechek E.R., Laing M.A., Girgis-Gabardo A.A., Siegel P.M., Cardiff R.D., Muller W.J. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res. 2003, 63:4920-4926.
2. Bai L., Rohrschneider L.R. s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev. 2010, 24:1882-1892.
3. Bouras T., Pal B., Vaillant F., Harburg G., Asselin-Labat M.L., Oakes S.R., Lindeman G.J., Visvader J.E. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 2008, 3:429-441.
4. Callahan R., Smith G.H. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene 2000, 19:992-1001.
5. Cardiff R.D. The pathology of EMT in mouse mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 2010, 15:225-233.
6. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat. Rev. Clin. Oncol. 2010, 7:683-692.
7. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., Perou C.M., Nielsen T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14:1368-1376.
8. Chow L.M., Endersby R., Zhu X., Rankin S., Qu C., Zhang J., Broniscer A., Ellison D.W., Baker S.J. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011, 19:305-316.
9. Cohen B., Bashirullah A., Dagnino L., Campbell C., Fisher W.W., Leow C.C., Whiting E., Ryan D., Zinyk D., Boulianne G., et al. Fringe boundaries coincide with Notch-dependent patterning centres in mammals and alter Notch-dependent development in Drosophila. Nat. Genet. 1997, 16:283-288.
10. Cohen B., Shimizu M., Izrailit J., Ng N.F., Buchman Y., Pan J.G., Dering J., Reedijk M. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res. Treat. 2010, 123:113-124.
11. Ding L., Ellis M.J., Li S., Larson D.E., Chen K., Wallis J.W., Harris C.C., McLellan M.D., Fulton R.S., Fulton L.L., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
12. Dong Y., Li A., Wang J., Weber J.D., Michel L.S. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Res. 2010, 70:5465-5474.
13. Duncan A.W., Rattis F.M., DiMascio L.N., Congdon K.L., Pazianos G., Zhao C., Yoon K., Cook J.M., Willert K., Gaiano N., Reya T. Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat. Immunol. 2005, 6:314-322.
14. Elsheikh S.E., Green A.R., Rakha E.A., Samaka R.M., Ammar A.A., Powe D., Reis-Filho J.S., Ellis I.O. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer 2008, 99:327-334.
15. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
16. Gastaldi S., Comoglio P.M., Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for?. Breast Cancer Res. 2010, 12:208.
17. Gatza M.L., Lucas J.E., Barry W.T., Kim J.W., Wang Q., Crawford M.D., Datto M.B., Kelley M., Mathey-Prevot B., Potti A., Nevins J.R. A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. USA 2010, 107:6994-6999.
18. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
19. Graveel C.R., DeGroot J.D., Su Y., Koeman J., Dykema K., Leung S., Snider J., Davies S.R., Swiatek P.J., Cottingham S., et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc. Natl. Acad. Sci. USA 2009, 106:12909-12914.
20. Haines N., Irvine K.D. Glycosylation regulates Notch signalling. Nat. Rev. Mol. Cell Biol. 2003, 4:786-797.
21. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010, 70:709-718.
22. Haughian J.M., Pinto M.P., Harrell J.C., Bliesner B.S., Joensuu K.M., Dye W.W., Sartorius C.A., Tan A.C., Heikkila P., Perou C.M., Horwitz K.B. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc. Natl. Acad. Sci. USA 2012, 109. 2742-2742.
23. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., Fridlyand J., Sahin A., Agarwal R., Joy C., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69:4116-4124.
24. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
25. Herschkowitz J.I., He X., Fan C., Perou C.M. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 2008, 10:R75.
26. Hochgräfe F., Zhang L., O'Toole S.A., Browne B.C., Pinese M., Porta Cubas A., Lehrbach G.M., Croucher D.R., Rickwood D., Boulghourjian A., et al. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 2010, 70:9391-9401.
27. Holstege H., Horlings H.M., Velds A., Langerød A., Børresen-Dale A.L., van de Vijver M.J., Nederlof P.M., Jonkers J. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010, 10:654.
28. Hrabě de Angelis M., McIntyre J., Gossler A. Maintenance of somite borders in mice requires the Delta homologue DII1. Nature 1997, 386:717-721.
29. Hvid H., Fels J.J., Kirk R.K., Thorup I., Jensen H.E., Hansen B.F., Oleksiewicz M.B. In situ phosphorylation of Akt and ERK1/2 in rat mammary gland, colon, and liver following treatment with human insulin and IGF-1. Toxicol. Pathol. 2011, 39:623-640.
30. Irvine K.D. Fringe, Notch, and making developmental boundaries. Curr. Opin. Genet. Dev. 1999, 9:434-441.
31. Jiang Z., Deng T., Jones R., Li H., Herschkowitz J.I., Liu J.C., Weigman V.J., Tsao M.S., Lane T.F., Perou C.M., Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J. Clin. Invest. 2010, 120:3296-3309.
32. Jiang Z., Jones R., Liu J.C., Deng T., Robinson T., Chung P.E.D., Wang S., Herschkowitz J.I., Egan S.E., Perou C.M., Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011, 10:1563-1570.
33. Johnston S.H., Rauskolb C., Wilson R., Prabhakaran B., Irvine K.D., Vogt T.F. A family of mammalian Fringe genes implicated in boundary determination and the Notch pathway. Development 1997, 124:2245-2254.
34. Jones R.A., Campbell C.I., Gunther E.J., Chodosh L.A., Petrik J.J., Khokha R., Moorehead R.A. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007, 26:1636-1644.
35. Klinakis A., Szabolcs M., Politi K., Kiaris H., Artavanis-Tsakonas S., Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc. Natl. Acad. Sci. USA 2006, 103:9262-9267.
36. Kobayashi S. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer 2008, 15:153-158.
37. Lee C.W., Raskett C.M., Prudovsky I., Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68:5273-5281.
38. Lee C.W., Simin K., Liu Q., Plescia J., Guha M., Khan A., Hsieh C.C., Altieri D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 2008, 10:R97.
39. Lee K.H., Choi E.Y., Kim M.K., Hyun M.S., Jang B.I., Kim T.N., Kim S.W., Song S.K., Kim J.H., Kim J.R. Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines. Exp. Mol. Med. 2006, 38:27-35.
40. Leong K.G., Niessen K., Kulic I., Raouf A., Eaves C., Pollet I., Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J. Exp. Med. 2007, 204:2935-2948.
41. Lim E., Vaillant F., Wu D., Forrest N.C., Pal B., Hart A.H., Asselin-Labat M.L., Gyorki D.E., Ward T., Partanen A., et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 2009, 15:907-913. kConFab.
42. Liu J.C., Deng T., Lehal R.S., Kim J., Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res. 2007, 67:8671-8681.
43. Lu X., Kambe F., Cao X., Yamauchi M., Seo H. Insulin-like growth factor-I activation of Akt survival cascade in neuronal cells requires the presence of its cognate receptor in caveolae. Exp. Cell Res. 2008, 314:342-351.
44. Molyneux G., Geyer F.C., Magnay F.A., McCarthy A., Kendrick H., Natrajan R., Mackay A., Grigoriadis A., Tutt A., Ashworth A., et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417.
45. Monaghan-Benson E., Mastick C.C., McKeown-Longo P.J. A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR. J. Cell Sci. 2008, 121:3693-3703.
46. Naldini L., Vigna E., Bardelli A., Follenzi A., Galimi F., Comoglio P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J. Biol. Chem. 1995, 270:603-611.
47. Niranjan B., Buluwela L., Yant J., Perusinghe N., Atherton A., Phippard D., Dale T., Gusterson B., Kamalati T. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 1995, 121:2897-2908.
48. Osipo C., Patel P., Rizzo P., Clementz A.G., Hao L., Golde T.E., Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032.
49. Panin V.M., Papayannopoulos V., Wilson R., Irvine K.D. Fringe modulates Notch-ligand interactions. Nature 1997, 387:908-912.
50. Parr C., Watkins G., Jiang W.G. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int. J. Mol. Med. 2004, 14:779-786.
51. Pece S., Serresi M., Santolini E., Capra M., Hulleman E., Galimberti V., Zurrida S., Maisonneuve P., Viale G., Di Fiore P.P. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 2004, 167:215-221.
52. Perou C.M., Børresen-Dale A.L. Systems Biology and Genomics of Breast Cancer. Cold Spring Harb. Perspect. Biol. 2011, 3.
53. Ponzo M.G., Lesurf R., Petkiewicz S., O'Malley F.P., Pinnaduwage D., Andrulis I.L., Bull S.B., Chughtai N., Zuo D., Souleimanova M., et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. USA 2009, 106:12903-12908.
54. Ponzo M.G., Park M. The Met receptor tyrosine kinase and basal breast cancer. Cell Cycle 2010, 9:1043-1050.
55. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., He X., Perou C.M. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12:R68.
56. Raafat A., Goldhar A.S., Klauzinska M., Xu K., Amirjazil I., McCurdy D., Lashin K., Salomon D., Vonderhaar B.K., Egan S., Callahan R. Expression of Notch receptors, ligands, and target genes during development of the mouse mammary gland. J. Cell. Physiol. 2011, 226:1940-1952.
57. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26:2568-2581.
58. Raouf A., Zhao Y., To K., Stingl J., Delaney A., Barbara M., Iscove N., Jones S., McKinney S., Emerman J., et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008, 3:109-118.
59. Ravid D., Maor S., Werner H., Liscovitch M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005, 24:1338-1347.
60. Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., Lockwood G., Egan S.E. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005, 65:8530-8537.
61. Reedijk M., Pinnaduwage D., Dickson B.C., Mulligan A.M., Zhang H., Bull S.B., O'Malley F.P., Egan S.E., Andrulis I.L. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res. Treat. 2008, 111:439-448.
62. Robinson D.R., Kalyana-Sundaram S., Wu Y.M., Shankar S., Cao X., Ateeq B., Asangani I.A., Iyer M., Maher C.A., Grasso C.S., et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 2011, 17:1646-1651.
63. Rui L., Emre N.C., Kruhlak M.J., Chung H.J., Steidl C., Slack G., Wright G.W., Lenz G., Ngo V.N., Shaffer A.L., et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010, 18:590-605.
64. Saal L.H., Gruvberger-Saal S.K., Persson C., Lövgren K., Jumppanen M., Staaf J., Jönsson G., Pires M.M., Maurer M., Holm K., et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 2008, 40:102-107.
65. Salani B., Briatore L., Garibaldi S., Cordera R., Maggi D. Caveolin-1 down-regulation inhibits insulin-like growth factor-I receptor signal transduction in H9C2 rat cardiomyoblasts. Endocrinology 2008, 149:461-465.
66. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
67. Savage K., Lambros M.B., Robertson D., Jones R.L., Jones C., Mackay A., James M., Hornick J.L., Pereira E.M., Milanezi F., et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 2007, 13:90-101.
68. Shackleton M., Vaillant F., Simpson K.J., Stingl J., Smyth G.K., Asselin-Labat M.L., Wu L., Lindeman G.J., Visvader J.E. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
69. Shimizu M., Cohen B., Goldvasser P., Berman H., Virtanen C., Reedijk M. Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res. 2011, 71:277-286.
70. Smolen G.A., Muir B., Mohapatra G., Barmettler A., Kim W.J., Rivera M.N., Haserlat S.M., Okimoto R.A., Kwak E., Dahiya S., et al. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 2006, 66:3452-3455.
71. Stein D., Wu J., Fuqua S.A., Roonprapunt C., Yajnik V., D'Eustachio P., Moskow J.J., Buchberg A.M., Osborne C.K., Margolis B. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994, 13:1331-1340.
72. Stella M.C., Trusolino L., Pennacchietti S., Comoglio P.M. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol. Cell. Biol. 2005, 25:3982-3996.
73. Stingl J., Eirew P., Ricketson I., Shackleton M., Vaillant F., Choi D., Li H.I., Eaves C.J. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
74. Stylianou S., Clarke R.B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66:1517-1525.
75. Sun T., Aceto N., Meerbrey K.L., Kessler J.D., Zhou C., Migliaccio I., Nguyen D.X., Pavlova N.N., Botero M., Huang J., et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell 2011, 144:703-718.
76. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., Hartwell K., Onder T.T., Gupta P.B., Evans K.W., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. USA 2010, 107:15449-15454.
77. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23:2563-2577.
78. Visvader J.E., Smith G.H. Murine Mammary Epithelial Stem Cells: Discovery, Function, and Current Status. Cold Spring Harb. Perspect. Biol. 2011, 3.
79. Wagner K.U., Wall R.J., St-Onge L., Gruss P., Wynshaw-Boris A., Garrett L., Li M., Furth P.A., Hennighausen L. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res. 1997, 25:4323-4330.
80. Xu K., Nieuwenhuis E., Cohen B.L., Wang W., Canty A.J., Danska J.S., Coultas L., Rossant J., Wu M.Y., Piscione T.D., et al. Lunatic Fringe-mediated Notch signaling is required for lung alveogenesis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 298:L45-L56.
81. Yalcin-Ozuysal O., Fiche M., Guitierrez M., Wagner K.U., Raffoul W., Brisken C. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ. 2010, 17:1600-1612.
82. Yamaguchi N., Oyama T., Ito E., Satoh H., Azuma S., Hayashi M., Shimizu K., Honma R., Yanagisawa Y., Nishikawa A., et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 2008, 68:1881-1888.
83. Zhang N., Gridley T. Defects in somite formation in lunatic fringe-deficient mice. Nature 1998, 394:374-377.